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ABSTRACT 
  Fatty alcohols are excipients that are abundantly used in various pharmaceutical 
formulations. The objective of the present study was to evaluate the impact of incorporating 
different fatty alcohols on microstructural and formulation characteristics of topical o/w 
clotrimazole cream formulation. The formulations containing different fatty alcohols as Kolliwax® 
CSA 50 (CSA 50), Kolliwax® CSA 70 (CSA 70), Kolliwax® MA (MA), Kolliwax® CA (CA), 
Kolliwax® SA (SA) were prepared by selecting suitable RPM and homogenization time. The M.P. 
of API and fatty alcohols were determined using DSC technique. The prepared cream formulations 
were evaluated for their phase separation. The various tests like pH, water activity measurement, 
work of adhesion measurement, globule size distribution, In vitro permeation study and 
rheological study were performed for the characterization of the formulation. All formulations 
were made in two batches and were subjected to stability conditions for 3 month at two conditions, 
25ᵒC/60% RH and 40ᵒC/75% RH respectively. The initial and 3 month samples were characterized 
using tests like, pH, water activity measurement and globule size distribution. 
The results for the tests like pH, water activity were found to be comparable in all cream 
formulations with different fatty alcohols. In phase separation study, the drug was found to have 
partitioned predominantly in the lipid phase with negligible amount present in the aqueous phase 
of the cream formulations.  The work of adhesion values for all fatty alcohols except SA were 
found to be in the same range of values. From the results of globule size distribution, it can be 
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concluded that CSA50, CSA70, MA and CA were found to form stable o/w cream formulation 
with a globule size range 2 to 6µm. SA when used alone in cream formulation, failed to produce a 
cream formulation with stable globules. All fatty alcohols containing creams showed yield stress 
values ~ 10 Pa, except for the SA sample, which displayed a very low yield stress.  The results of 
the rheological studies revealed that CSA 50 and CSA 70 form relatively stable microstructure. 
As, all products are shear thinning and have comparable yield stress, the rheological characteristics 
clearly reflect the microstructural similarities in the formulations. The results of finite and infinite 
IVPT studies revealed that the permeation of clotrimazole from all the o/w topical cream 
formulations could be enhanced when MA and CA are used in the formulation. The cream products 
prepared with different fatty alcohols maintained same characteristics at two storage conditions. 
SA was found to be one of the less efficient fatty alcohol in terms of forming a good o/w cream in 
the present case.         
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CHAPTER I 
INTRODUCTION 
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  Pharmaceutical cream formulations are heterogeneous semisolid systems in which drug is 
either dissolved or dispersed in water in oil (w/o) or oil in water (o/w) emulsion. They are widely 
used in topical application of the drugs1. An o/w cream besides being non-occlusive in nature also 
has emollient properties as it can lead to deposition of lipids and moisturizers on and into the 
stratum corneum2. 
The basic ingredients used in cream formulations are emollients, viscogens, emulsifying 
agents, vehicles, penetration enhancers. It is extremely important to select appropriate combination 
of these ingredients to formulate a stable topical cream formulation. Fatty alcohols are excipients 
that are abundantly used in various pharmaceutical formulations. Chemically, fatty alcohols are 
aliphatic hydrocarbons with a hydroxyl group at the terminal position and are derived from either 
plants or animal oils and fats. 
Inactive Ingredient database of FDA has 44 listings of approved NDA topical formulations 
with different fatty alcohols like myristyl alcohol, cetyl alcohol, stearyl alcohol or cetostearyl 
alcohol3. There are also approved generic topical semi-solid products that contain different fatty 
alcohols which can be identified at US National institute of Health Daily Med database4 
Fatty alcohols play multiple roles leading to development of topical products of desired 
efficacy, safety and stability. Fatty alcohols are used in creams to impart the desired sensorial and 
functional characteristics to the formulation. They can influence texture characteristics and 
improve the rheological properties of topical products. They act as solubility enhancers for some 
of the poorly soluble APIs. They can also play the role of permeation enhancer by improving the 
drug penetration into as well as across the skin.  
3 
 
 
Fatty alcohols were found to influence the rate of metamorphosis of the cream product after 
application on the skin. The rate of drying and metamorphosis of the product on the skin surface 
determines the extent of dermal absorption of therapeutic agents. The fatty alcohols also found to 
influence the spreadability, spreading area, skin cooling and work of adhesion properties of the 
topical products. Incorporation of  fatty alcohols  as a part of any pharmaceutical or cosmetic cream 
formulation helps the formulator to impart the desired characteristics to the product by the way of 
changing the fatty alcohol type and ratio. The type of vehicle used in the topical formulation can 
also play an important role in permeation of drug. The solubility of drug in different components 
of formulation and in stratum corneum can influence partitioning of drug from the dosage form5,6.  
Clotrimazole is an azole derivative having a broad-spectrum antifungal activity. The drug 
is known to act by binding to cytochrome P 450 enzymes, which are required for demethylation 
of lanosterol to ergosterol. Ergosterol concentrations get reduced leading to damaged and leakage 
in the cell membranes leading to the prevention of fungal growth7. The chemical structure of 
clotrimazole is as shown in Figure 18. 
 
                                                        
 
Figure 1: Chemical structure of clotrimazole 
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 It is used to treat skin infections like athlete’s foot, jock itch, ringworm. It also can be used 
to treat a skin condition called as pityriasis and for fungal infection that causes a lightening or 
darkening of the skin in the area of the neck, chest, arms or legs9. 
Clotrimazole is commonly formulated in the form of topical cream and most of these 
formulations are available over the counter. Few examples of FDA approved products containing 
clotrimazole as an active ingredient are described in Table 1. 
 
Table 1: FDA approved products containing clotrimazole 
Product Name Strength Dosage form/route Company 
MYCELEX(10) 1% Solution; topical Bayer Healthcare 
MYCELEX-7(11) 1%   Cream; vaginal Bayer Healthcare LLC 
CLOTRIMAZOLE(12) 1% Cream; vaginal Taro 
                                           
There is a need of studying the influence of commercially available pharmacopoeial grade 
fatty alcohols on a drug-containing cream modeled after commercially available clotrimazole 
formulations as a majority of the studies reported have been based on simple model systems with 
water, emulsifier and fatty alcohols. 
Hence, the present study focused on evaluating influence of fatty alcohols on the 
characteristics and performance of the topical o/w cream formulation containing clotrimazole.  
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CHAPTER II 
OBJECTIVE OF THE STUDY 
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The objective of the present study was to evaluate the influence of fatty alcohols on 
formulation characteristics and dermal delivery of clotrimazole. Clotrimazole containing topical 
O/W cream formulations with different fatty alcohols were prepared and characterized. 
Research Strategy: The formulations containing different fatty alcohols  such as 
Kolliwax®CSA 50( CSA 50), Kolliwax® CSA 70 (CSA 70), Kolliwax®MA (MA), Kolliwax® 
CA(CA) , Kolliwax® SA (SA) were prepared at set homogenization protocol. The API and fatty 
alcohols were characterized by determination of M.P. by DSC. The various tests like pH, water 
activity measurement, work of adhesion measurement, globule size distribution and rheological 
study were performed for the characterization of the formulation.  
In vitro permeation studies at finite and infinite dose conditions were performed across porcine 
epidermis model using Franz diffusion cells. All formulations were made in two batches and were 
subjected to stability conditions for 3 months. Formulations were kept at two conditions, 25ᵒC/60% 
RH and 40ᵒC/75% RH respectively. The initial and 3 month samples were characterized for pH, 
water activity measurement and globule size distribution. 
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CHAPTER III 
MATERIALS AND METHODS 
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Materials 
                 Clotrimazole (≥ 98%) was gifted by YRROW CHEM PRODUCTS, Mumbai. 
Kolliwax®CSA 50 (cetostearyl alcohol 50), Kolliwax® CSA 70 (cetostearyl alcohol 70), 
Kolliwax®MA (myristyl alcohol), Kolliwax® CA (cetyl alcohol), Kolliwax® SA (stearyl alcohol), 
Kollisolv™ PG (propylene glycol), Kollicream™ OD (octyldodecanol) and Kolliphor™ CS 20 
(macrogol cetostearyl ether 20) were gifted by BASF. Euxyl 320 and Nile Red were purchased 
from Sigma Aldrich. High Performance Liquid Chromatography (HPLC)-grade solvents like 
methanol, ethanol were purchased from Fisher Chemicals, USA. Porcine skin was obtained from 
Pontotoc Slaughterhouse, Pontotoc, MS, USA. The wide mouth containers (10 oz.) were purchased 
from U Line suppliers. 
Methods 
 
Table 2: Preparation of clotrimazole containing o/w formulations 
Ingredient Description Purpose  w/w% 
Kollisolv™ PG Propylene glycol Solvent 8 
Fatty alcohol# Fatty alcohol   Viscogen 9 
Kollicream™ OD Octyldodecanol Emollient 6 
Kolliphor™ CS 20 Macrogol cetostearyl ether 20 Emulsifier 1 
Active Ingredient Clotrimazole (clz) API 1 
Water -  Solvent 75 
Euxyl 320 Phenoxyethanol Preservative q.s. 
Nile Red  Dye 0.0005 
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Table 3: The list of fatty alcohols with their brand names 
Fatty alcohol# 
Brand Name Chemical Name 
Kolliwax® CSA 50 Cetostearyl alcohol 50 
 Kolliwax®  CSA 70 Cetostearyl alcohol 70 
Kolliwax® MA Myristyl alcohol 
Kolliwax®  CA Cetyl alcohol 
           Kolliwax® SA Stearyl alcohol 
 
The formula for the cream preparation was used as mentioned in Table 2 and fatty alcohols 
used in the study were as shown in Table 3. Aqueous and lipid phase were heated separately at 
60ᵒC. Lipid phase was added slowly with the constant speed to the aqueous phase. Both the phases 
were homogenized for 30 minutes at 3000 RPM in Silverson Homogenizer L5M-A (Silverson 
Machines INC, USA). The constant temperature was maintained during the transfer and 
homogenization of both the phases. Propylene glycol along with the Clotrimazole API was added 
at the end of the 30 minutes followed by the cooling program. Cooling program- 60ᵒC to 25ᵒC in 
20 minutes was given using VWR cooling/heating probe and throughout the cooling, speed of 
3000 RPM in Silverson Homogenizer L5M-A was maintained. These batches were made in the 
quantity of 300 gm. The brief steps involved in the preparation of topical O/W cream were as 
shown in Figure 2. 
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Figure 2: Steps in preparation of topical o/w cream 
HPLC Analysis  
             An isocratic HPLC method was developed for the quantification of clotrimazole3. The 
experiment was performed using a Waters HPLC system (Water 600 Controller, USA) equipped 
with a 600-pump unit, a 717 plus auto sampler with an injection valve with a sample loop of 50 
µl, and a 2487 dual absorbance UV detector.  The 10mmM solution of dibasic potassium phosphate 
was made and was used with acetonitrile. The mobile phase had acetonitrile and buffer (3:1 v/v) 
and was delivered at a flow rate of 1 ml/min. Then, 20 µl of the injection was eluted in column. 
The calibration curve was prepared using different concentrations of API in the range of 1µg to 
10ng and methanol: water (90:10 v/v) was used as a solvent. LOD, LOQ were determined.  
 
 
 
                                                                       
 
 
Aqueous 
Phase 
60ᵒC 
Homogenization for 
30 minutes at 3000 
RPM 
Oil Phase 
Cooling Program: 60ᵒC to 
25ᵒC in 20 minutes at 3000 
RPM 
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Measurement of M.P.using DSC 
           The M.P. of all five fatty alcohols were determined using DSC 25 (TA Instruments 
Delaver, USA) technique. The M.P. of the API was also determined. Around 7 mg of powdered 
sample was placed in Tzero Hermetic Pan and was sealed with Tzero lid. The pan was placed in 
the sample chamber along with the reference pan and analysis was done by using Ramp method 
with the rate of 10ᵒC/min. 
pH measurement 
           The pH of the creams was measured by using Mettler Toledo Inc. USA pH meter. The 
probes used in the study are METTLER TOLEDO InLab®Science Pro, 0….12.0, 0….100ᵒ C and 
METTLER TOLEDO InLab®Micro, 0….12.0, 0….100ᵒC. The pH meter was calibrated using 
standard buffers with the known pH of 4.0, 7.0 and 10.0 respectively. The pH of each cream 
formulation was measured thrice. In between every individual measurement, the pH using buffer 
standard of pH 4.0 and using buffer standard of pH 10.0 after the next measurement was noted. 
Phase separation study 
             The study was performed by weighing 1 gm of each sample in eppendorf. The samples 
were subjected to centrifugation at 50,000 RPM in Beckman Coulter centrifugation instrument 
(Beckman Coulter Inc USA). All formulations were centrifuged for 8 hrs. The separated oil phase 
and aqueous phase were weighed separately. The 2mg of oil phase was diluted to 50 ml with 
methanol and aqueous phase was diluted by adding 2 ml of methanol. The samples were subjected 
to HPLC analysis. The distribution of drug in both the phases was evaluated. 
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  Water Activity measurement 
           The water activity of all cream formulations was measured by using AQUALAB water 
activity meter series 3 and 3TE (Series 3E, USA) as shown in Figure 3.  All measurements were 
performed at 32ᵒ C. The instrument was calibrated using DI water and the water activity of each 
formulation was recorded. The DI water was taken in sampling cup and kept in the sampling 
chamber of the instrument. The values were noted thrice and the instrument was found to be 
suitable if the water activity for DI water comes equal to 1.00. The samples were analyzed in 
triplicate and the average of the values was reported. 
                                           
Figure 3: Water activity meter (Series 3E, USA) 
 
 
Work of Adhesion   
The test was performed using TA-XT2i Texture Analyser (Texture Technologies Corp) as 
shown in Figure 4. TA3 1" dia cylinder,w.radius,acrylic probe as shown in Figure 5. was used for 
the measurement of work of adhesion of the samples10,11.                                               
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Globule size measurement 
The globule size of the cream formulation was measured by using Axio Cam HR3 (Carl 
Zeiss Microscopy, Germany) bright field microscopy at the magnification scale of 50 x 2.5. The 
thin smear of the cream was prepared with the help of coverslip on the glass slide and observed 
immediately under the microscope. For each cream, the mean diameter of randomly distributed 
100 globules was measured using the Zen Lite software. The globule size measurement was done 
by calculating d10, d50 and d90 values for each cream. 
Rheological Study 
The rheology of all samples were studied using TA Instruments HR2 Rheometer (TA 
Instruments, New Castle, DE)  at 32 °C with 20 mm parallel plate with 600 grit sandpaper and 
solvent trap. 
Figure 4: Texture Analyzer (TAXT2i, Texture Tech. Corp., Scarsdale, NY) 
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In vitro Drug Permeation Study 
  A fresh porcine skin was brought from a local slaughterhouse. The abdominal skin regions 
were taken and shaved using an electric shaver. The hairless skin was cut into small rectangular 
pieces. Then, the pieces were covered with aluminium foil and immersed in a water bath 
maintained at 60 ºC for 2 min. After 2 min, the aluminium foil was removed and the epidermis 
was carefully mounted by hand on clean glass slides. Then, the epidermis was kept for 12 h until 
it was completely dried and then was stored in a refrigerator at 5 ºC for future use. The in vitro 
skin permeation study was performed using Franz diffusion cells with an effective diffusion area 
of 0.64 cm2. A hairless porcine epidermis was sandwiched between the donor and receiver 
medium with the SC side facing the donor compartment. The receiver compartment (5ml)/were 
filled with an ethanol/PBS solution (30:70) as a reservoir solution12 and was maintained at 37 °C.  
 The dose for infinite dose study was 300 mg/cm2, and that for finite dose study was 10 mg 
/cm2 respectively. The infinite dose study was carried out as the dose is several fold higher than 
the clinically relevant dose and at such high dose, the influence of drying and metamorphosis of 
the product would be negligible.  The steady state flux is a good parameter to understand the 
formulation and API related properties in relevance to drug delivery. The finite dose studies would 
be close to clinically relevant dose and   it would reveal the way the formulation would behave 
and perform in real life situation. 
 During the IVPT studies, the entire receiver compartment was fluid was withdrawn at the 
time points of 0,2,4,8 and 12h and replaced by equal quantities of fresh medium.  The amount of 
clotrimazole in these samples was quantified and determined using HPLC. The cumulative amount 
of drug permeated at different time points was plotted and steady state flux was calculated from 
15 
 
 
the slope of the line in infinite dose study.  Whereas in finite dose study, the midpoint average flux 
was calculated and plotted to determine the maximum flux (Jmax) and AUC0-t 
 The porcine epidermis was selected as the stratum corneum has been reported to be closely 
resemble in terms of structure and composition with human stratum corneum13. The porcine skin 
is found to have a comparable drug permeability with human skin14. Porcine skin has shown 
histological as well as biochemical similarities with human skin14,15,16,17. 
 
Stability Studies 
The quantity of 20 gm from each drug-containing batch was kept for stability studies. The 
samples were kept at conditions of 25ᵒC/60% RH and 40ᵒC/75% RH for 3 months in stability 
chambers. The samples were withdrawn and analysed for initial and 3 months.  
 
Following tests were performed at each time interval, 
1.  Microscopy i.e. globule size measurement 
2.  pH determination 
3. Water activity measurement
16 
 
 
CHAPTER IV 
RESULTS AND DISCUSSION
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HPLC analysis 
 
Table 4: HPLC results for different clotrimazole standard preparations 
Concentration 
(μg/ml) 
Area 
1 472432 
0.75 278827 
0.5 255131 
0.25 133342 
0.1 56464 
0.05 25702 
0.025 18783 
0.01 11072 
            
          
 
 
Figure 5: Clotrimazole standard calibration curve 
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  From Table 4, the LOQ was found to be at 10 ng. The concentration lower than 10 ng was 
detectable but was not being able to get quantified by the HPLC method. As shown in Figure 5, 
the calibration curve was plotted and the value of R2 was found to be 0.97 which indicated that 
regression line correctly fits with the data.          
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Physicochemical properties of fatty alcohols 
M.P. for different fatty alcohols were found to be as shown in Figure 6. Different 
physicochemical properties of fatty alcohols were as shown in Table 4. 
        
Figure 6: M.P. determination of fatty alcohols using DSC technique 
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Table 5: Physicochemical properties of fatty alcohols 
       
 
Measurement of pH of topical o/w cream formulations 
 
Table 6: pH values for topical o/w cream formulation 
 
 
 
 
 
 
 
 CSA 50 CSA 70 CA SA MA 
M.P 51.97ᵒC 54.3ᵒC 49.3°C 59.5°C 38°C 
C-chain length (21-24) 16-18 16-18 C16 C18 C14 
Avg. Mol. Wt.(21-24) 
512.94 
g/mol 
512.94 
g/mol 
242.43 
g/mol 
270.48 
g/mol 
214.39 
g/mol 
log P (22-24) 7.53 7.25 6.83 8.22 6.03 
Name pH 
CSA 50  5.75 ± 0.05 
CSA 70 5.89 ± 0.02 
CA 5.79 ± 0.02 
SA 5.79 ± 0.01 
MA 5.79 ± 0.01 
21 
 
 
Clotrimazole is weakly basic in nature18. As per the pH/partition theory, the unionized drug 
has more ability to permeate compared to the ionized form of the drug.  We have earlier found that 
the pH of the topical products could change post application on the skin to homeostasis with the 
pH of the skin, pH 5. As in this case, the initial pH of the formulation is close to 5, there is less 
concern about any change in the ionized/unionized drug ratio due to meager changes in the pH of 
the formulation.          
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 Phase distribution study 
Table 7: Phase separation study for topical o/w cream formulation 
    
Clotrimazole in 
each phase(μg) 
Clotrimazole in 
each phase/gm of 
sample(mg) 
Total 
amount of 
drug (mg) 
CSA 
50 
Oil Layer 8577.60 8.58 
9.19 
Intermediate  
waxy Layer 
599.93 0.60 
Aqueous Layer 8.71 0.01 
CSA 
70 
waxy Oil Layer 9040.232 9.04 
9.27 
Intermediate 
waxy Layer 
22.09 0.22 
Aqueous Layer 3.14 0.00 
CA 
Oil Layer 10852.86 10.85 
11.21 
Intermediate 
waxy Layer 
348.04 0.35 
Aqueous Layer 4.50 0.00 
SA 
Oil Layer 10775.13 10.78 
10.98 
Intermediate 
waxy Layer 
204.60 0.20 
Aqueous Layer 1.29 0.00 
MA 
Oil Layer 11246.40 11.25 
11.35 
Intermediate 
waxy Layer 
102.33 0.10 
Aqueous Layer 0.70 0.00 
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In case of all the creams, the drug was found to have partitioned predominantly in the 
lipid phase with negligible amount present in the aqueous phase as seen in Table 7. 
Water Activity measurement 
 
Table 8: Water activity measurement of clotrimazole containing o/w creams with different 
fatty alcohol 
Name Water Activity (aw) 
CSA 50 0.97 ± 0.00 
CSA 70 0.97 ± 0.00 
CA 0.96 ± 0.00 
SA 0.97 ± 0.00 
MA 0.99 ± 0.01 
  
   
 
 
  Water activity values give idea about the microbial stability of the formulation19. Water 
activity is simply defined as the ratio of the vapor pressure of pure water (100% equilibrium 
relative humidity) over the vapor pressure of the sample. Water activity can have influence on the 
drug permeation from the formulation as it was found that water activity gradient between outer 
layers of skin and formulation vehicle can change the amount of water loss from skin19. Being o/w 
cream in nature, the values were found to be higher as shown in Table 8. The water activity values 
were found comparable for all fatty alcohols. 
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Work of adhesion 
 
Table 9: Work of adhesion measurement of Clotrimazole containing o/w creams with 
different fatty alcohols 
Name  
Work of  Adhesion 
(g.sec) 
CSA 50 27.48 ± 0.68 
CSA 70 20.50 ± 0.04 
CA 26.70 ± 0.69 
SA 17.04 ± 0.37 
MA 25.75 ± 0.62 
 
As shown in Table 9, work of adhesion values for all fatty alcohols except SA were found 
to be in the same range of values. Work of adhesion could be the sensitive tool for determination 
of parameters like spreadability of the cream formulation. 
    The Young- Dupre equation, gives an idea about the surface tensions of liquid, soild and 
surface tension at the interface of solid-liquid along with the contact angle between them20, 
                                                         Wab = ᵞ1(1+ cos) 
Wab = work of adhesion between two phases, ᵞ = surface tension and cos = contact angle  
The work of adhesion is an interfacial phenomenon as it helps in determining force required 
to separate solid surface from the liquid surface. 
From the results mentioned in Table 9, the SA has low work adhesion indicating the more 
spreadability of the formulation.  
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Globule size measurement 
 
Table 10: Globule size measurement of clotrimazole containing o/w creams with different 
fatty alcoholsITIAL 
Name  d10  (µm) d50 (µm) d90 (µm) 
CSA 50 2.61 ± 0.00 4.05 ± 0.07 5.45 ± 0.21 
CSA 70 2.50 ± 0.14 3.90 ± 0.42 5.20 ± 0.57 
CA 2.55 ± 0.07 3.75 ± 0.35 4.90 ± 0.71 
SA N.A. N.A. N.A. 
MA 2.05 ± 0.07 3.05 ± 0.07 3.80 ± 0.10 
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Figure 7: Photomicrographs and globule size distribution for clotrimazole creams 
containing different fatty alcohols 
 As shown in Table 10 and Figure 7, the globule size distribution of creams containing CSA 
50 was found to have d10, d50 and d90 as 2.6 ± 0.01 , 4.0 ± 0.06 and 5.4 ± 0.23µm respectively. 
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CSA 50. However in cream containing SA, emulsification was not complete and globules were 
found to be irregular and larger in size. 
From the results of globule size distribution, it can be concluded that CSA50, CSA70, MA 
and CA were found to form stable o/w cream formulation with a globule size range 2 to 6 µm. SA 
when used alone in cream formulation, failed to produce a cream formulation with stable globules. 
 
Rheological study 
In semisolid emulsions, surfactants and fatty alcohol contribute towards formation of 
viscoelastic gel network which helps in stabilizing the oil droplets into the water phase. Type of 
surfactant whether ionic or nonionic along with its homologous composition affect the structure 
of the gel network. This phenomenon results in giving particular appearance and rheological 
stability to the formulation21,22.The surfactant emulsifiers reduce the surface tension which helps 
in easy breakdown of droplets during the emulsification process. This process facilitates 
formation of viscoelastic gel network. Higher mixed emulsifier concentrations lead to linkage of 
crystalline and gel phases forming a semisolid cream23. The mixtures which form lamellar phases 
in the bulk can form strong viscoelastic films at the interface23,24. Fatty alcohols have tendency of 
swelling in the presence of nonionic surfactant. Surfactant gets interpositioned between the 
alcohol molecules and alpha crystals of alcohol resulting in swelling because of the hydration 
POE chains of the surfactant20,25,21. 
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Figure 8: Yield Stress study for clotrimazole creams containing different fatty alcohol 
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Figure 9: Stress vs shear rate study for clotrimazole containing o/w creams with different 
fatty alcohols 
 
Table 11: Viscosities at different shear rates of clotrimazole containing o/w creams with 
different fatty alcohols 
  
  0.01 
(1/s) 
At the shear 
rate: 20 s-1 
Yield 
Stress (Pa) 
CSA50 2397 N/A 16 
CSA70 1838 N/A 13 
CA 3137 3.6 9 
SA 1132 1.3 1 
MA 1276 1.5 12 
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  Previous studies have reported reduction in consistency of formulations containing cetyl 
alcohol and stearyl alcohol during the storage period21. The yield stress values as shown in Figure 
8 and Table 11. All fatty alcohols containing creams showed yield stress values ~10 Pa, except for 
the SA sample, which displayed a very low yield stress.  When stress vs shear rate was plotted, 
there was increasing shear rate (forward) with decrease in viscocity for all samples, indicating that 
the samples were shear thinning as seen in Figure 9. The hysteresis has been found to be highest 
in SA sample. CSA 50 and CSA 70 samples did not display any significant hysteresis indicating 
that their ability to impart robustness to the products. Shear thinning behaviour of cream 
formulation gives an idea about the spreadability of the formulation and it is an indicative of 
stability of the formulation26. 
The results of the rheological studies revealed that CSA 50 and CSA 70 form relatively 
stable microstructure. This could be attributed to the fact that cetostearyl alcohol can stabilize the 
emulsion due to lamellar gel network. Also, cetostearyl alcohol provides stability to the 
formulation due to chain-length mismatch which is not found in the pure cetyl alcohol nor stearyl 
alcohol. Chain-length mismatch also reduces the melting enthalpy in comparison to pure fatty 
alcohols27. As, all products were found to be shear thinning and have comparable yield stress, the 
rheological characteristics clearly reflect the microstructural similarities in the formulations. 
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In vitro Drug permeation study using infinite dose study for o/w cream formulations 
 
 
 
 
 
 
 
 
 
 
0.0
0.3
0.6
0.9
0 2 4 6 8 10 12
C
u
m
u
la
ti
v
e 
a
m
o
u
n
t 
p
er
m
ea
te
d
 
(µ
g
/c
m
2
)
Time(h)
CSA 50
CSA70
CA
SA
MA
Figure 10: IVPT profile of clotrimazole at Infinite Dose from clotrimazole containing O/W cream 
[n=2 donors (3-6 replicate each donor ±SEM)] 
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Table 12: Clotrimazole O/W cream infinite dose IVPT study Steady state flux values and 
physicochemical properties of fatty alcohols 
 
 
                   
         
 
 
 
 
 
 
 
 
Figure 11: The relationship between steady state flux and M.P. of each fatty alcohol 
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        Fatty alcohol 
Steady state flux 
(µg/cm2/h) 
M.P.(ᵒC) 
CSA 50 0.028 ± 0.011 51.97 
CSA 70 0.015 ± 0.004 54.3 
CA 0.041 ± 0.021 49.3 
SA 0.015 ± 0.004 59.5 
MA 0.064 ± 0.028 38 
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Fatty alcohols have shown an ability to act as effective permeation enhancers of drugs in 
many formulations14. The steady state flux of drug from o/w creams containing different fatty 
alcohols was determined from the cumulative release versus flux data as shown in Table 12 and 
Figure 10. The results clearly show that the type of fatty alcohol incorporated has a significant 
impact on the drug permeation from o/w creams. Creams incorporated with MA and CA resulted 
in higher permeation of clotrimazole than those prepared with CSA50.  
In the present work, it was presumed that the drug permeation could depend on the ability of fatty 
alcohols to interact with stratum corneum lipids by disrupting the densely packed lipids in the 
extracellular spaces of the stratum corneum14.  
  In 1990, Flynn proposed that physicochemical properties of chemicals can influence their 
permeation through skin28. Potts and Guy established quantitative correlation between 
physicochemical properties such as molecular weight, log P of molecule and flux across the skin29.  
 
log kp = - 2.7 + 0.71* log P- 0.0061*MW 
    kp= permeability coefficient, log P = partition coefficient, MW = molecular weight 
Barratt30 extended the Potts and Guy equation by using melting point and molecular volume 
to predict the permeability of the molecules. He performed multiple regression analysis of log PC 
against log P(partition coefficient),molecular volume and melting point. 
             log PC = - 0.00484*MV + 0.71* log P- 0.00515*MP-2.655 
      PC= permeability coefficient, log P = partition coefficient, MV= molecular volume, 
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                      MP =melting point 
  Hence, the same concept was used to establish the correlation between the steady state flux 
and melting point of fatty alcohols in the present study. There was an inverse correlation as shown 
in Figure 11, observed between the steady state flux of drug (which in turn shows the extent of 
modulation of skin permeability by the fatty alcohol) with melting point of the fatty alcohol 
incorporated in the cream product. This explains the reason why the permeation of clotrimazole in 
cream with MA, was found to have more drug permeation than creams having fatty alcohols with 
higher melting point. 
 
In vitro Drug permeation study using finite dose study for o/w cream formulations 
The finite dose permeation flux versus time profile followed a typical up and down curve 
in all the cases as shown in Figure 12. The J (max) values from CSA 50 and 70 were comparable 
and was lesser than other fatty alcohols used in neat form as seen in Figure 13 and Table 13. 
Myristyl alcohol and cetyl alcohol containing formulation resulted in a significantly higher Jmax 
values than the other fatty alcohols. The AUC for the formulations containing MA and CA was 
found to be higher compared to other fatty alcohols as shown in Table 14 and Figure 14. Although 
Tmax was different, the Jmax was comparable between MA and CA. 
The results of finite and infinite studies revealed that the permeation of clotrimazole from 
all the o/w topical cream formulations could be enhanced when MA and CA are used in the 
formulation.         
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Figure 12: IVPT profile of clotrimazole at finite Dose from clotrimazole containing O/W 
cream [n=2 donors (3-6 replicate each donor ±SEM) 
 
 
Table 13: IVPT finite dose study Jmax and standard error of means for clotrimazole  
creams containing different fatty alcohols 
       Fatty alcohol J (max) (µg/cm2/h) ± SEM 
CSA 50 0.102 ± 0.070 
CSA 70 0.247 ± 0.110 
CA 0.663 ± 0.351 
SA 0.166 ± 0.059 
MA 0.635 ± 0.279 
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Figure 13: IVPT profile of clotrimazole at finite Dose study J max for clotrimazole 
containing o/w cream 
 
 
Table 14: IVPT finite dose study Area under the curve and standard error of means for 
clotrimazole creams containing different fatty alcohols 
 Fatty alcohol AUC (µg/cm2) 
CSA 50 0.184 ± 0.132 
CSA 70 0.618 ± 0.443 
CA 1.835 ± 1.122 
SA 0.321 ± 0.176 
MA 1.211 ± 0.602 
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Figure 14: The Area under the curve from IVPT profile of clotrimazole at finite dose for 
clotrimazole containing o/w cream 
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Stability Study 
Table 15: Results for initial samples of clotrimazole containing o/w creams with different 
fatty alcohols 
 
Table 16: Stability study results for 3-month samples at 25ᵒC/60% RH of clotrimazole 
containing o/w creams with different fatty alcohols 
3M (25ᵒC/65% RH) 
 CSA 50 CSA 70 CA SA MA 
  Avg. Avg. Avg. Avg. Avg. 
pH 
7.30 ± 0.05 7.23 ± 0.02 7.11 ± 0.01 7.30 ± 0.01 6.87 ± 0.01 
Water Activity 
(aw) 
0.98 ± 0.00 0.97 ± 0.00 0.99 ± 0.00 0.98 ± 0.00 0.98 ± 0.00 
d10 (µm) 
2.60 ± 0.14 2.45 ± 0.21 1.90 ± 0.28 N.A 2 .30 ± 0.0 
d50 (µm) 
4.00 ± 0.28 3.80 ± 0.28 3.50 ± 0.00 N.A 3.30 ± 0.14 
d90 (µm) 
5.45 ± 0.35 5.05± 0.21 5.10 ± 0.14 N.A. 4.25 ± 0.05 
INITIAL 
 CSA 50 CSA 70 CA SA MA 
 Avg. Avg. Avg. Avg. Avg. 
pH 5.75 ± 0.05 5.89 ± 0.02 5.79 ± 0.02 5.79 ± 0.01 5.79 ± 0.01 
Water 
Activity (aw) 
0.97 ± 0.00 0.97 ± 0.00 0.96 ± 0.00 0.97 ± 0.00 0.998 ± 0.00 
d10 (µm) 2.61 ± 0.00 2.50± 0.14 2.55 ± 0.07 N.A 2 .05 ± 0.07 
d50 (µm) 4.05 ± 0.07 3.90 ± 0.42 3.75 ± 0.35 N.A 3.05 ± 0.07 
d90 (µm) 5.45 ± 0.21 5.20± 0.57 4.90 ± 0.71 N.A. 3.80 ± 0.10 
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Table 17: Stability study results for 3-month samples at 40ᵒC/75% RH of clotrimazole 
containing O/W creams with different fatty alcohols 
3M (40ᵒC/75% RH) 
 CSA 50 CSA 70 CA SA MA 
 Avg. Avg. Avg. Avg. Avg. 
pH 
7.15 ± 0.01 6.65 ± 0.01 6.96 ± 0.01 6.89 ± 0.01 6.32 ± 0.01 
Water Activity 
(aw) 
0.97 ± 0.00 0.98 ± 0.00 0.98 ± 0.00 0.98 ± 0.00 0.99 ± 0.00 
d10 (µm) 
2.25 ± 0.21 2.25 ± 0.21 1.75 ± 0.49 N.A 2 .15 ± 0.07 
d50 (µm) 
3.85 ± 0.21 3.60 ± 0.00 2.80 ± 0.85 N.A 3.20 ± 0.14 
d90 (µm) 
5.25 ± 0.21 5.05 ± 0.35 4.25 ± 1.20 N.A. 4.35 ± 0.07 
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Figure 15: Photomicrograph for initial samples of clotrimazole containing o/w creams with 
CSA 50 
 
Figure 16: Photomicrograph for 3M 25°C/60%RH samples for clotrimazole containing 
O/W creams with CSA 50 
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Figure 17: Photomicrograph for 3M 40°C/75%RH samples for clotrimazole containing o/w 
creams with CSA 50 
 
 
Figure 18: Photomicrograph for initial samples for clotrimazole containing O/W creams 
with CSA 70 
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Figure 19: Photomicrograph for 3M 25°C/60%RH samples for clotrimazole containing o/w 
creams with CSA 70 
 
 
Figure 20: Photomicrograph for 3M 40°C/75%RH samples for clotrimazole containing o/w  
creams with CSA 70 
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Figure 21: Photomicrograph for initial samples for clotrimazole containing o/w creams 
with CA 
 
Figure 22: Photomicrograph for 3M 25°C/60%RH samples for clotrimazole containing o/w  
creams with CA 
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Figure 23: Photomicrograph for 3M 40°C/75%RH samples for clotrimazole containing 
O/W creams with CA 
 
 
 
 
Figure 24: Photomicrograph for initial samples for clotrimazole containing o/w creams 
with SA 
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Figure 25: Photomicrograph for 3M 25°C/60%RH samples for clotrimazole containing o/w 
creams with SA 
 
Figure 26: Photomicrograph for 3M 40°C/75%RH samples for clotrimazole containing o/w 
creams with SA 
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Figure 27: Photomicrograph for initial samples for clotrimazole containing o/w creams 
with MA 
     
 
 
Figure 28: Photomicrograph for 3M 25°C/60%RH samples for clotrimazole containing o/w 
creams with MA 
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Figure 29: Photomicrograph for 3M 40°C/75%RH samples for clotrimazole containing o/w  
creams with MA 
       
       
  As shown in Table 15-17, the products prior to storage had pH values in the range of 5.75 
± 0.05 to 5.89 ± 0.02 and it did change significantly at both the storage conditions. This change 
could be because of the change in the partitioning of fatty acids from aqueous phase to lipid phase 
leading to increase in the pH of the formulation. 
The water activity results were not altered and were found to be in the same range of 0.97 
± 0.00 to 0.99 ± 0.00. The d10, d50 and d90 values for initial samples were found to be in the same 
range as that of 3 month old samples and the globule size distribution was also found to be closer 
to initial values for all the cream products except for cream product containing SA which showed 
irregular shaped globules leading to poor globule size distribution. The results are expressed as 
mean ± SEM in all cases and as mean ± SD in case of globule size distribution. The microscopical 
images for all samples at both the storage conditions are as shown in Figure 15-30. 
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The cream products prepared with different fatty alcohols maintain same characteristics at 
two storage conditions. SA was found to be one of the less efficient fatty alcohol in terms of 
forming a good o/w cream in the present case.  
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CHAPTER V 
CONCLUSION 
52 
 
 
The pH, water activity and globule size were found to be in the same range for cream 
formulations containing different fatty alcohols. CSA 50 and CSA 70 containing creams were 
found to have stable microstructure during rheological evaluations. Cream containing SA did not 
form a proper emulsion as evident from microscopic study, texture analysis and rheology. In 
infinite and finite dose IVPT studies, MA containing cream showed higher transdermal 
permeation of clotrimazole. A good correlation was found between the steady state flux of 
clotrimazole and melting point of fatty alcohols. The cream formulations with different fatty 
alcohols showed stable results of water activity and globule size at both the storage conditions. 
However, pH values changed significantly during stability study. Hence, it was concluded that 
fatty alcohols can play different roles like permeation enhancer, stabilizing agent, viscogen in 
formulation. The formulator can select either the single or combination of fatty alcohols for 
achieving desired characteristics in the formulation. 
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